Float Short %

24.66

Margin Of Safety %

Put/Call OI Ratio

0.18

EPS Next Q Diff

0.18

EPS Last/This Y

-0.17

EPS This/Next Y

2.03

Price

19.99

Target Price

35.25

Analyst Recom

1.25

Performance Q

13.25

Relative Volume

1.01

Beta

1.34

Ticker: URGN

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-12-26	URGN	23	0.19	0.02	21404
2025-12-29	URGN	23.28	0.19	0.06	21393
2025-12-30	URGN	23.19	0.19	1.27	21392
2025-12-31	URGN	23.41	0.19	5.55	21423
2026-01-02	URGN	22.69	0.19	0.16	21388
2026-01-05	URGN	22.13	0.19	0.16	21440
2026-01-06	URGN	21.89	0.19	0.03	21517
2026-01-07	URGN	23.14	0.19	0.00	21498
2026-01-08	URGN	23.49	0.19	0.00	21522
2026-01-09	URGN	21.45	0.19	0.16	21464
2026-01-12	URGN	21.46	0.19	0.09	21851
2026-01-13	URGN	19.85	0.18	0.14	22195
2026-01-14	URGN	18.71	0.18	0.02	22301
2026-01-15	URGN	19.55	0.18	0.72	22885
2026-01-16	URGN	18.83	0.18	0.82	22954
2026-01-20	URGN	19.37	0.18	0.02	21610
2026-01-21	URGN	19.43	0.18	0.12	21625
2026-01-22	URGN	20.03	0.18	0.06	21974
2026-01-23	URGN	20.01	0.18	1.46	22001
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-12-26	URGN	23.02	38.9	-	-3.13
2025-12-29	URGN	23.33	38.9	-	-3.13
2025-12-30	URGN	23.18	38.9	-	-3.13
2025-12-31	URGN	23.42	38.9	-	-3.13
2026-01-02	URGN	22.67	38.9	-	-3.13
2026-01-05	URGN	22.11	38.9	-	-3.13
2026-01-06	URGN	21.91	38.9	-	-3.13
2026-01-07	URGN	23.16	38.9	-	-3.13
2026-01-08	URGN	23.47	38.9	-	-3.13
2026-01-09	URGN	21.23	38.9	-	-3.13
2026-01-12	URGN	21.41	38.9	-	-3.13
2026-01-13	URGN	19.84	38.9	-	-3.13
2026-01-14	URGN	18.71	38.9	-	-3.13
2026-01-15	URGN	19.54	38.9	-	-3.13
2026-01-16	URGN	18.78	38.9	-	-3.13
2026-01-20	URGN	19.33	38.9	-	-3.13
2026-01-21	URGN	19.24	38.9	-	-3.13
2026-01-22	URGN	20.04	38.9	-	-3.13
2026-01-23	URGN	19.99	38.9	-	-3.13
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-12-26	URGN	-0.46	7.11	20.00
2025-12-29	URGN	-0.46	7.13	20.00
2025-12-30	URGN	-0.46	7.13	20.00
2025-12-31	URGN	-0.46	7.13	20.00
2026-01-02	URGN	-0.46	7.13	20.00
2026-01-05	URGN	-0.46	8.23	20.00
2026-01-06	URGN	-0.46	8.23	20.00
2026-01-07	URGN	-0.46	8.23	20.00
2026-01-08	URGN	-0.46	8.23	20.00
2026-01-09	URGN	-0.46	8.23	20.00
2026-01-12	URGN	-0.41	8.23	20.00
2026-01-13	URGN	-0.46	8.23	24.66
2026-01-14	URGN	-0.46	8.23	24.66
2026-01-15	URGN	-0.46	8.23	24.66
2026-01-16	URGN	-0.46	8.23	24.66
2026-01-20	URGN	-0.46	8.67	24.66
2026-01-21	URGN	-0.46	8.67	24.66
2026-01-22	URGN	-0.46	8.67	24.66
2026-01-23	URGN	-0.46	8.67	24.66
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

-0.69

Avg. EPS Est. Current Quarter

-0.49

Avg. EPS Est. Next Quarter

-0.51

Insider Transactions

-0.46

Institutional Transactions

8.67

Beta

1.34

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

33.4

Max Drawdown 5-Year %

-85.4

Target Price

35.25

P/E

Forward P/E

PEG

P/S

9.7

P/B

P/Free Cash Flow

EPS

-3.46

Average EPS Est. Cur. Y

-3.13

EPS Next Y. (Est.)

-1.1

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-170.59

Relative Volume

1.01

Return on Equity vs Sector %

115.4

Return on Equity vs Industry %

131.4

EPS 1 7Days Diff

EPS 1 30Days Diff

0.03

EBIT Estimation

UroGen Pharma Ltd.

Sector: Healthcare

Industry: Biotechnology

Employees: 287

UroGen Pharma Ltd. engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; and Jelmyto for pyelocalyceal solution. The company's lead product candidate are UGN-102 for pyelocalyceal solution; UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301, UGN-301+ UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

stock quote shares URGN – UroGen Pharma Ltd. Stock Price stock today

news today URGN – UroGen Pharma Ltd. stock forecast ,stock prediction 2023 2024 2025

marketwatch URGN – UroGen Pharma Ltd. yahoo finance google finance

stock history URGN – UroGen Pharma Ltd. invest stock market

stock prices URGN premarket after hours

ticker URGN fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: URGN

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y